Autoimmune disease risk may differ by menopausal hormone therapy formulation

Progestogen, when used in hormone therapy, is recognized for its benefits in protecting the uterus. A new study suggests that its addition limits the increased risk of composite autoimmune disease associated with estrogen-only therapy. Results of the study were presented at the 2026 Annual Meeting of The Menopause Society in San Diego, Oct. 20–24, 2026.

Read it at Medical Xpress ↗

← Front page